NAFLD: A multisystem disease - Google Scholar Metrics

Articles citing NAFLD: A multisystem disease

Title / Author	Year
The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases N Chalasani, Z Younossi, JE Lavine, M Charlton, K Cusi, M Rinella, ... Hepatology 67 (1), 328-357	2018
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease C Estes, H Razavi, R Loomba, Z Younossi, AJ Sanyal Hepatology 67 (1), 123-133	2018
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis G Targher, CD Byrne, A Lonardo, G Zoppini, C Barbui Journal of hepatology 65 (3), 589-600	2016
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis S Ballestri, S Zona, G Targher, D Romagnoli, E Baldelli, F Nascimbeni, ... Journal of gastroenterology and hepatology 31 (5), 936-944	2016
NAFLD and diabetes mellitus H Tilg, AR Moschen, M Roden Nature reviews Gastroenterology & hepatology 14 (1), 32-42	2017
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904	2018
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications SM Francque, D van der Graaff, WJ Kwanten Journal of hepatology 65 (2), 425-443	2016
Non-alcoholic fatty liver disease and dyslipidemia: an update N Katsiki, DP Mikhailidis, CS Mantzoros Metabolism 65 (8), 1109-1123	2016
Epidemiology and natural history of non-alcoholic fatty liver disease Y Fazel, AB Koenig, M Sayiner, ZD Goodman, ZM Younossi Metabolism 65 (8), 1017-1025	2016
Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? A Lonardo, F Nascimbeni, A Mantovani, G Targher Journal of hepatology 68 (2), 335-352	2018
Non-alcoholic fatty liver disease and risk of cardiovascular disease A Lonardo, S Sookoian, CJ Pirola, G Targher Metabolism 65 (8), 1136-1150	2016
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease G Arguello, E Balboa, M Arrese, S Zanlungo Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852 (9 …	2015
NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk S Ballestri, F Nascimbeni, E Baldelli, A Marrazzo, D Romagnoli, ... Advances in therapy 34 (6), 1291-1326	2017
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions A Lonardo, F Nascimbeni, G Targher, M Bernardi, F Bonino, E Bugianesi, ... Digestive and Liver Disease 49 (5), 471-483	2017
Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis A Mantovani, CD Byrne, E Bonora, G Targher Diabetes care 41 (2), 372-382	2018
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies N Stefan, HU Häring, K Cusi The lancet Diabetes & endocrinology 7 (4), 313-324	2019
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement VG Athyros, TK Alexandrides, H Bilianou, E Cholongitas, M Doumas, ... Metabolism 71, 17-32	2017
Pathogenesis of nonalcoholic steatohepatitis W Liu, RD Baker, T Bhatia, L Zhu, SS Baker Cellular and Molecular Life Sciences 73 (10), 1969-1987	2016
Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates PX Wang, YX Ji, XJ Zhang, LP Zhao, ZZ Yan, P Zhang, LJ Shen, X Yang, ... Nature medicine 23 (4), 439-449	2017
Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease-Where do we stand? I Mikolasevic, L Orlic, N Franjic, G Hauser, D Stimac, S Milic World journal of gastroenterology 22 (32), 7236	2016

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.